Results 161 to 170 of about 54,010 (241)

A case report of advanced pancreatic cancer patient demonstrating remarkable efficacy with liposomal irinotecan after failure of multiple-line therapies. [PDF]

Front Oncol
Yu S, Zhu H.
europepmc   +1 more source

Is FOLFIRINOX more effective than gemcitabine plus nab-paclitaxel in pancreatic adenocarcinoma? -a decade of debate! [PDF]

J Gastrointest Oncol
Babiker HM.
europepmc   +1 more source

Zolbetuximab combined with chemotherapy in a patient with CLDN18.2-positive advanced gastric cancer undergoing hemodialysis: a case report. [PDF]

Front Oncol
Zhao Y, Jin Y, Fu L, Yao D, Zhou Z, Dong Y, Tan Y.   +6 more
europepmc   +1 more source

Survival of patients with colorectal or pancreatic cancer who received <i>UGT1A1</i> genotype-guided dosing of irinotecan in the Netherlands (2017-2024): a retrospective, multicentre cohort study. [PDF]

Lancet Reg Health Eur
Peeters SLJ, Heersche N, Böhm D, Böhringer S, Guiljam R, Hulshof EC, de Man FM, de With M, Joosse M, Oomens G, Wu QY, Osman A, Bins S, van Hellemond IEG, Haberkorn BCM, Verschoor AJ, Wumkes ML, van Schaik RHN, Thijs AM, Gelderblom H, Guchelaar HJ, Mathijssen RHJ, Deenen MJ.   +22 more
europepmc   +1 more source

Cost-effectiveness of switching to S-1 after fluoropyrimidine-induced hand-foot syndrome or cardiovascular toxicity in the treatment of metastatic colorectal cancer. [PDF]

ESMO Open
van Eekelen R, Punt CJA, Kwakman JJM, Coupé VMH.   +3 more
europepmc   +1 more source

Efficacy of steroid-omitting antiemetic therapy in patients with advanced pancreatic cancer receiving nano-liposomal irinotecan plus fluorouracil and leucovorin. [PDF]

Support Care Cancer
Tokito Y, Ishigaki K, Nara K, Endo G, Nishio H, Fukuda K, Suzuki T, Sato Y, Takahara N, Boku N, Fujishiro M.   +10 more
europepmc   +1 more source

NALIRIFOX versus liposomal irinotecan plus fluorouracil/leucovorin as the second-line chemotherapy in gemcitabine refractory pancreatic adenocarcinoma: a real-world study. [PDF]

Ther Adv Med Oncol
Wong WZ, Chiang NJ, Lee KC, Yu HY, Tsai CJ, Hsu SJ, Lee PC, Chen MH, Huang HC, Li CP, Luo JC, Lee FY.   +11 more
europepmc   +1 more source

Predictors of prolonged progression-free survival in patients with unresectable or recurrent pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid (NAPOLEON-2 study). [PDF]

Ther Adv Med Oncol
Kawaguchi Y, Hayashi K, Shimokawa M, Otsuka T, Nakazawa J, Shimokawa H, Shinohara Y, Koga F, Oza N, Oda H, Takeshita S, Arima S, Arita S, Nishikawa K, Otsu S, Taguchi H, Jikuya K, Sakai T, Ueda Y, Sakae T, Araki N, Sawase H, Ide Y, Kawahira M, Nio K, Shirakawa T, Mizuta T, Mitsugi K.   +27 more
europepmc   +1 more source

Molecular Determinants of Response and Rational Drug Combinations for Antibody-Drug Conjugates (ADCs) with Topoisomerase I (TOP1) Inhibitor Payloads. [PDF]

J Mol Biol
Pommier Y.
europepmc   +1 more source

Old tale new admirers, cetuximab maintenance in metastatic colorectal cancer: a systematic review and meta-analysis. [PDF]

Front Pharmacol
Yan Y, Lin Z, Yuan J, Gao W, Jiao C, Sun L, Sun X.   +6 more
europepmc   +1 more source